The most recent clinical trials, conducted under randomised, placebo-controlled protocols, have shown significant improvements after ten weeks of use. Patients experienced measurable benefits in multiple areas: reduced anxiety, improved sleep quality, increased concentration and a decrease in suicidal thoughts. In addition, evidence accumulated over more than twenty years confirms the absence of serious side effects<\/strong>.<\/p>\n\n\n\n In the British case, the Leicestershire Partnership NHS Trust (LPT)<\/strong> was a pioneer in integrating this device into its mental health crisis unit, where more than 160 patients participated in a pilot programme. The results were overwhelming: suicidal thoughts were reduced by one-third in just three weeks and by two-thirds after ten weeks.<\/p>\n\n\n\n The success of the UK model has attracted the interest of European healthcare systems. Countries such as Sweden, Denmark, Germany and Spain<\/strong> already have suppliers of neuromodulation devices certified for clinical use, including:<\/p>\n\n\n\n In Spain, several private clinics and research centres have begun to explore tDCS as an alternative for drug-resistant patients, although it is not yet funded by the public system. As in the UK, many of these initiatives rely on support from foundations, patient associations and private donations.<\/p>\n\n\n\n Dr Mark McConnochie, a consultant psychiatrist for the NHS in Leicester, stresses that this technology could become a key tool for those who find no response from medication:<\/p>\n\n\n\n \"The possibility of offering an effective treatment, without relevant adverse effects, opens a path of hope for many patients who have exhausted their therapeutic options.<\/p>\n<\/blockquote>\n\n\n\n As depression and anxiety become entrenched as the main causes of main causes of sick leave and hospitalisation in young people in Europe<\/strong>experts agree that the integration of technology in mental health<\/strong> can make a difference. Initiatives such as these not only represent a medical breakthrough, but also respond to the urgency of strengthening health systems with innovative, accessible and sustainable treatments.<\/p>","protected":false},"excerpt":{"rendered":" Varios sistemas de salud europeos est\u00e1n evaluando la expansi\u00f3n de programas piloto en prevenci\u00f3n del suicidio mediante el uso de dispositivos de estimulaci\u00f3n cerebral no invasiva, tras observar resultados muy prometedores en Reino Unido con el casco Flow Neuroscience, desarrollado en Suecia. El dispositivo emplea Estimulaci\u00f3n Transcraneal por Corriente Directa (tDCS), una t\u00e9cnica que aplica […]<\/p>\n","protected":false},"author":2,"featured_media":5298,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73,25],"tags":[357,356,185],"class_list":["post-5297","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mental","category-salud","tag-neuro-modulacion","tag-prevencion-del-suicidio","tag-salud-mental"],"yoast_head":"\n\n
![\"\"](\"https:\/\/wellnessforum.pro\/wp-content\/uploads\/2025\/09\/HIGH358325_643415_632949-1024x576.jpg\")
<\/figure>\n\n\n\n\n